Puma Biotechnology, Inc. (PBYI)
Nasdaq · Healthcare · Biotechnology
$9.67+1.68%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $499M
- P/E (trailing)
- 19.0
- Forward P/E
- 27.6
- 52-week range
- $4.58 – $10.10
- 52-week change
- +83.59%
- EPS (trailing)
- $0.51
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $228M (−0.91%)
- Net income
- $31.1M
- Operating margin
- 16.3%
- Diluted EPS
- $0.61
- Free cash flow
- $41.7M
From the company’s annual report on SEC EDGAR.
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc.
Headquarters: Los Angeles, United States · 179 employees · pumabiotechnology.com